On July 21, 2025, dental medical technology company ZimVie Inc. announced that it had reached a final agreement with ARCHIMED, an investment company focused on the healthcare sector, and that its affiliates would complete the acquisition at a cash price of $19.00 per share.
The transaction values ZimVie at approximately $730 million, a premium of 99% over its 90-day volume-weighted average price of $9.57.
Vafa Jamali, chairman of the board and CEO of ZimVie, said that this transaction not only demonstrates the market value accumulated by the company in recent years, but also injects new impetus into the company’s future development.
He pointed out: “Joining hands with ARCHIMED will bring strategic and financial support to the company, allowing our innovative dental solutions to benefit patients around the world more widely.”
André-Michel Ballester, Managing Partner of ARCHIMED, also expressed his expectations for this cooperation: “ZimVie has solid fundamentals and significant growth potential. We are pleased to support it in its new stage of development.”
According to the announcement, the transaction has been unanimously approved by ZimVie’s board of directors and is expected to be completed by the end of 2025. The transaction is still subject to approval by shareholders and relevant regulatory authorities, but there is no financing prerequisite. ZimVie will continue to operate as an independent company before the completion of the transaction.
After the completion of the transaction, ZimVie will become a privately held company and its shares will be delisted from Nasdaq. In addition, the agreement has a 40-day “bid period” during which ZimVie can seek more attractive bid proposals with the assistance of its financial advisor Centerview Partners.
The period will last until midnight New York time on August 29, 2025. During this period, the company does not plan to disclose relevant progress unless the board of directors decides otherwise.
In this transaction, Centerview Partners served as financial advisor to ZimVie, and Cravath, Swaine & Moore LLP provided legal services.
ARCHIMED’s financial advisor was UBS Investment Bank, and its legal advisor was Latham & Watkins LLP.
ZimVie, headquartered in Palm Beach Gardens, Florida, focuses on the research, development and manufacturing of dental implant technology, biomaterials and digital dental workflows.
ARCHIMED is an investment company spanning Europe, North America and Asia, focusing on market segments such as medical technology, biopharmaceuticals, diagnostics and medical information technology.
